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Pharmacokinetics of Adjusted-Dose Lopinavir-Ritonavir Combined
with Rifampin in Healthy Volunteers
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Coadministration of lopinavir-ritonavir, an antiretroviral protease inhibitor, at the standard dose (400/100
mg twice a day [BID]) with the antituberculous agent rifampin is contraindicated because of a significant
pharmacokinetic interaction due to induction of cytochrome P450 3A by rifampin. In the present study, two
adjusted-dose regimens of lopinavir-ritonavir were tested in combination with rifampin. Thirty-two healthy
subjects participated in a randomized, two-arm, open-label, multiple-dose, within-subject controlled study. All
subjects were treated with lopinavir-ritonavir at 400/100 mg BID from days 1 to 15. From days 16 to 24, the
subjects in arm 1 received lopinavir-ritonavir at 800/200 mg BID in a dose titration, and the subjects in arm
2 received lopinavir-ritonavir at 400/400 mg BID in a dose titration. Rifampin was given at 600 mg once daily
to all subjects from days 11 to 24. The multiple-dose pharmacokinetics of lopinavir, ritonavir, and rifampin
were assessed. Twelve of 32 subjects withdrew from the study. For nine subjects lopinavir-ritonavir combined
with rifampin resulted in liver enzyme level elevations. Pharmacokinetic data for 19 subjects were evaluable.
Geometric mean ratios for the lopinavir minimum concentration in serum and the maximum concentration in
serum (Cmax) on day 24 versus that on day 10 were 0.43 (90% confidence interval [CI], 0.19 to 0.96) and 1.02
(90% CI, 0.85 to 1.23), respectively, for arm 1 (n  10) and 1.03 (90% CI, 0.68 to 1.56) and 0.93 (90% CI, 0.81
to 1.07), respectively, for arm 2 (n  9). Ritonavir exposure increased from days 10 to 24 in both arms. The
geometric mean Cmax of rifampin was 13.5 mg/liter (day 24) and was similar between the two arms. Adjusted-
dose regimens of lopinavir-ritonavir in combination with therapeutic drug monitoring and monitoring of liver
function may allow concomitant use of rifampin.
The treatment of human immunodeficiency virus (HIV)-
infected individuals has improved greatly over the past several
years. With the development of antiretroviral agents in differ-
ent classes, more options for the effective suppression of the
virus have become available (6). However, many problems
remain to be solved. One of them is the treatment of patients
presenting with HIV infection and coinfections. Tuberculosis
is a significant opportunistic infection in HIV-infected individ-
uals in developing countries and, to a lesser extent, in devel-
oped countries (1, 3, 11, 15). For public health reasons, active
tuberculosis must be treated immediately (3). The treatment of
HIV infection can be postponed on the basis of CD4 cell
counts and the viral load. However, depending on the clinical
and biochemical parameters for coinfected patients, simulta-
neous treatment of both infections can become indicated in
particular situations. The combination of antiretroviral therapy
with therapy with antituberculous agents is complex. In partic-
ular, the use of rifampin is hampered due to significant drug-
drug interactions. Rifampin is a first-line antibacterial agent
for the treatment of tuberculosis and acts by inhibiting the
DNA-dependent RNA polymerase of the microorganism (2).
Rifampin is a strong inducer of cytochrome P450 (CYP)-me-
diated metabolism of other agents; in particular, the CYP3A
isoenzyme is subject to induction. Rifampin metabolism itself
is not dependent on CYP3A; nevertheless, autoinduction of
cholinesterase- and B esterase-mediated metabolism of ri-
fampin has been shown (2).
Because of its CYP3A-inducing effects, rifampin is known to
produce significant pharmacokinetic interactions with HIV
protease inhibitors (PIs) and nonnucleoside reverse transcrip-
tase inhibitors (NNRTIs) (13). These pharmacokinetic inter-
actions may lead to subtherapeutic levels of these antiretroviral
agents in plasma, and for this reason, rifampin in combination
with most PIs and NNRTIs is contraindicated. This clearly
limits the options for highly active antiretroviral therapy in
Mycobacterium tuberculosis-coinfected HIV-infected patients.
Data on the adjusted dosages that generally result in thera-
peutic levels of the antiretrovirals in plasma have been pub-
lished for the PI saquinavir (17) and the NNRTI efavirenz
(10). Pharmacokinetic interactions between rifampin and nu-
cleoside reverse transcriptase inhibitors (NRTIs) are less pro-
nounced, since these agents do not undergo appreciable oxi-
dative metabolism (4, 14). A study of the interaction of
rifampin with T-20 (enfuvirtide) did not reveal clinically sig-
nificant changes in the pharmacokinetics of T-20 (Fuzeon;
Summary of Product Characteristics, 2003; Roche Registration
Limited, Welwyn Garden City, United Kingdom).
Lopinavir-ritonavir is a formulation of two PIs approved for
the treatment of HIV infection at a standard dosage of 400/100
* Corresponding author. Mailing address: Department of Clinical
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mg twice a day (BID) in combination with other antiretrovirals.
The coformulation of lopinavir-ritonavir is available as cap-
sules with a dose of 133 mg of lopinavir and 33 mg of ritonavir
per capsule. Lopinavir is mainly dependent on CYP3A for its
metabolism, and ritonavir is a strong inhibitor of CYP3A. For
this reason, ritonavir is coformulated with lopinavir (Kaletra
Product Information, 2000; Abbott Laboratories, Chicago,
Ill.), resulting in sustained and elevated plasma lopinavir levels.
The pharmacokinetic interaction between rifampin and lopi-
navir-ritonavir has been studied previously (R. Bertz, A. Hsu,
W. Lam, L. Williams, C. Renz, M. D. Karol, S. Dutta, A. Carr,
Y. Zhang, Q. Wang, S. Schweitzer, C. Foit, A. Andre, B.
Bernstein, G. Granneman, and E. Sun, 5th Int. Congr. Drug
Ther. HIV Infect., abstr. P291, 2000). The area under the
concentration-time curve (AUC) and the minimum concentra-
tion in plasma (Cmin) for lopinavir in healthy subjects were
reduced 75 and 99%, respectively, as a result of coadministra-
tion of rifampin at 600 mg once daily (QD) with lopinavir-
ritonavir at 400/100 mg BID. This is the direct result of the
strong induction of CYP3A by rifampin, which overcomes the
inhibition of CYP3A by low-dose ritonavir. Therefore, ri-
fampin combined with lopinavir-ritonavir in the standard-dose
regimen is contraindicated. The objective of the present study
was to investigate in healthy subjects the pharmacokinetics of
two adjusted-dose regimens of lopinavir-ritonavir in combina-
tion with rifampin in comparison to the standard dose of lopi-
navir-ritonavir without rifampin.
MATERIALS AND METHODS
Study design. The study was designed as a randomized, phase I, open-label,
two-arm, within-subject controlled study with 32 healthy subjects, both males and
females. See Table 1 for details of the study design. The study consisted of a
run-in period of 10 days in which lopinavir-ritonavir at the standard dose (400/
100 mg BID as three coformulated capsules) was given to all subjects. On study
day 10, the steady-state pharmacokinetics of lopinavir and ritonavir were deter-
mined over the daytime 12-h dosing interval. During study days 11 to 15, subjects
were dosed with lopinavir-ritonavir at the standard dosage, and rifampin at 600
mg QD was added to the regimen. After study day 15, subjects were randomized
to either arm 1 or arm 2. From day 16, a dose-titration phase was started in order
to diminish dose-related toxicity. In the last phase of the study (study days 18 to
24), the subjects in arm 1 were dosed with lopinavir-ritonavir at 800/200 mg BID
plus rifampin at 600 mg QD, while subjects in arm 2 were dosed with lopinavir-
ritonavir at 400/400 mg BID plus rifampin at 600 mg QD. The steady-state
pharmacokinetics of lopinavir, ritonavir, and rifampin were studied on study day
24.
During the study both rifampin and lopinavir-ritonavir were to be taken
together immediately after breakfast in the morning; 12 h later, lopinavir-ritona-
vir was to be taken after dinner.
For the pharmacokinetic analysis, the study subjects were confined on the day
prior to blood draw (days 9 and 23) until after the last blood draw on study days
10 and 24. From the day before the start of confinement, the subjects were not
allowed to consume alcohol. During confinement, subjects consumed only the
standardized scheduled meals and beverages provided at the research unit. The
subjects fasted from midnight on study days 9 and 23 to the time of breakfast on
study days 10 and 24. Water intake was not allowed from 1 h before until 2 h after
drug intake. The study medication was taken orally after breakfast (550 kcal,
28% fat) with 200 ml of noncarbonated water. After the intake of medication the
subjects had to remain in an upright position for at least 2 h. After dosing, the
subjects continued fasting (no food or beverages) until 5 h after drug intake, at
which time the subjects received a standardized lunch. The subjects received a
standardized snack at 9 h following drug ingestion, and dinner was served after
the last blood draw. Beverages (i.e., water, orange juice, apple juice, coffee, tea,
and milk) were allowed ad libitum from 5 h after dosing until the end of the
confinement period.
Selection of subjects. This study was performed with healthy subjects. The
inclusion criteria were the ability to sign voluntary informed consent; age 18
years or older; good health (i.e., the subject was not suffering from an acute or
chronic illness and was not using medications); and a body mass index (BMI)
lower than 30.0 for men and lower than 28.6 for women (body mass index is equal
to weight [in kilograms]/height2 [in square meters]). Female subjects could not be
of childbearing potential, defined as being postmenopausal for at least 1 year or
surgically sterile (by bilateral tubal ligation, bilateral oophorectomy, or hyster-
ectomy), or could be of childbearing potential but practicing one of the following
methods of birth control: condoms, sponge, foams, jellies, diaphragm or intra-
uterine device, vasectomy for the sexual partner, or total abstinence from sexual
intercourse. Exclusion criteria were as follows: known hypersensitivity to lopina-
vir, ritonavir, or rifampin; positive test result for HIV; positive test result for
hepatitis B or C virus; a tuberculin skin test reaction of more than 15 mm or a
tuberculin skin test reaction of 1 to 15 mm with a chest X-ray with abnormalities
consistent with tuberculosis; pregnancy or breastfeeding; body weight 50 kg;
use of contact lenses; a history of pancreatitis; a history of alcohol abuse; and one
or more of the following laboratory test results: hemoglobin concentration, 7.5
mM; leukocyte count, 3  109/liter; aspartate aminotransferase (ASAT) and
alanine aminotransferase (ALAT) levels more than two times the upper limit of
normal (ULN); -glutamyltransferase (GGT) levels more than two times the
ULN; alkaline phosphatase levels more than two times the ULN; serum creat-
inine levels more than 1.5 times the ULN; (pancreatic) amylase levels more than
two times the ULN; or total bilirubin levels more than two times the ULN.
Blood sampling procedure. For determination of lopinavir and ritonavir con-
centrations, blood samples (5 ml) were collected predosing and at 2, 4, 6, 8, 10,
and 12 h postingestion on days 10 and 24. Rifampin concentrations were deter-
mined with the same samples used for determination of lopinavir and ritonavir
concentrations on day 24. However, additional blood samples (5 ml) for the more
precise determination of the maximum concentration in plasma (Cmax) for ri-
fampin were drawn at 1 and 3 h postingestion on day 24. The subjects returned
to the study location on study days 1, 3, 7, 13, 16, 17, 18, 20, and 22 for predose
blood sampling (5 ml) for determination of lopinavir and ritonavir concentra-
tions. Blood samples were centrifuged at approximately 1,000  g for 10 min at
4°C. Plasma for determination of lopinavir and ritonavir concentrations was
transferred to a labeled polypropylene tube and stored at 18°C within 2 h
after collection. Plasma for determination of rifampin concentrations was trans-
ferred to a labeled polypropylene tube containing ascorbic acid and was stored at
80°C within 2 h after collection.
TABLE 1. Study design
Randomisation
Regimen(s) administered on the following daysa:
16 17 18–24
Arm1 LPV/r, 533/133 mg BID; RIF, 600
mg QD
LPV/r, 667/167 mg BID; RIF, 600
mg QD
LPV/r, 800/200 mg BID; RIF, 600
mg QD
Arm2 LPV/r, 400/200 mg BIDb; RIF,
600 mg QD
LPV/r, 400/300 mg BIDb; RIF,
600 mg QD
LPV/r, 400/400 mg BIDb; RIF,
600 mg QD
a From days 1 to 10, all subjects received lopinavir-ritonavir at 400/100 mg BID; and from days 11 to 15, all subjects received lopinavir-ritonavir at 400/100 mg BID
plus rifampin at 600 mg QD. The subjects were randomized to arm 1 or arm 2 after day 15. On days 10 and 24, blood sampling was performed up to 12 post ingestion.
Lopinavir-ritonavir. (LPV/r) was coformulated in capsules, each of which contained 133 mg of lopinavir and 33 mg of ritonavir. A lopinavir-ritonavir dose of 400/100
mg BID therefore consisted of three capsules. Rifampin (RIF) was dosed as two capsules, each of which containing 300 mg of rifampin.
b In the combinations with lopinavir-ritonavir at 400/200 mg BID, 400/300 mg BID, and 400/400 mg BID, the extra ritonavir was dosed as 100-mg ritonavir capsules
in addition to the normal combination of lopinavir-ritonavir at 400/100 mg.
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Bioanalysis. Plasma lopinavir and ritonavir levels were determined by a vali-
dated high-performance liquid chromatography (HPLC) method, which was a
modified version of a previously published method (9). The modification con-
sisted of a switch of the UV detection wavelength from 245 to 215 nm at 15.5
min, with retention times of 14.4 min for ritonavir and 15.8 min for lopinavir. The
concentration of each agent could be measured without interference from the
other drug. The lopinavir and ritonavir calibration curves were linear over a
range of 0.045 to 30.0 mg/liter. The lower limit of quantification was 0.04 mg/liter
for both lopinavir and ritonavir. Rates of recovery after extraction from plasma
were 95% for lopinavir and 94% for ritonavir. The accuracies ranged from 99 to
101% for lopinavir and from 92 to 100% for ritonavir, and the intraday precisions
ranged from 0.92 to 5.16% for lopinavir and from 1.51 to 5.14% for ritonavir.
The interday precisions ranged from 0 to 1.57% for lopinavir and from 0 to
5.00% for ritonavir.
Plasma rifampin levels were measured by a validated HPLC method that was
developed in the University Medical Centre Nijmegen but that has not yet been
published. The method consisted of protein precipitation followed by reversed-
phase HPLC with UV detection. Two hundred microliters of acetonitrile was
added to 200 l of plasma to precipitate protein. This mixture was vortexed for
20 s, and afterwards the mixture was centrifuged for 5 min. Fifty microliters of
the clear supernatant was used for injection. Chromatographic analysis was
performed on an Inertsil 5 ODS 2 analytical column (250 by 4.6 mm [inner
diameter]; Varian, Bergen op Zoom, The Netherlands) protected with a Chrom-
guard HPLC column (10 by 3 mm[inner diameter]; Varian). The mobile phase
was a mixture of 0.01 M potassium dihydrogen phosphate (62%) and acetonitrile
(38%). The flow rate was 1 ml/min, and the wavelength for UV detection was 334
nm. The rifampin retention time was 7.3 min. The rifampin calibration curve was
linear over a range of 0.50 to 30.0 mg/liter. The lower limit of quantification for
rifampin was 0.50 mg/liter. Recovery after extraction from plasma was 108.5%.
Accuracy ranged from 101.3 to 102.2%, and intraday and interday precisions
ranged from 2.84 to 3.65% and from 1.59 to 3.68%, respectively.
Safety monitoring and laboratory safety. The medical history, vital signs, a
physical examination, and an electrocardiogram for each subject were obtained
at screening. Laboratory tests were done at screening and all study visits (days 1,
3, 7, 10, 13, 16, 17, 18, 20, 22, and 24). Laboratory tests included tests for sodium,
potassium, creatinine, total bilirubin, cholesterol, triglycerides, glucose, alkaline
phosphatase, ASAT, ALAT, GGT, and amylase (pancreatic) levels; a whole-
blood cell count; and urinalysis.
Additionally, subjects were asked about the occurrence of adverse events at
each visit. Adverse events were assessed for intensity, according to the AIDS
Clinical Trials Group classifications mild (symptoms do not interfere with daily
activities), moderate (symptoms interfere with daily activities), and severe (symp-
toms markedly interrupt daily activities), and seriousness. Serious adverse events
were defined as any untoward medical occurrence that at any dose resulted in
death, that was life threatening, that required in-patient hospitalization or pro-
longation of existing hospitalization, that resulted in a persistent or significant
disability or incapacity, or that was a congenital anomaly or birth defect. During
the study, the occurrence of grade 2 toxicity, according to World Health Orga-
nization scales, would result in discontinuation of a subject from the study
medication. For cholesterol and triglycerides, grade 3 toxicity was a reason to
discontinue study medication.
Pharmacokinetic analysis. Values for the pharmacokinetic parameters of lopi-
navir, ritonavir, and rifampin were estimated by noncompartmental methods.
The Cmax and the time to Cmax (Tmax) were determined directly from the plasma
concentration-time data. Cmin and the morning predosing observed trough con-
centration in plasma (C0) were also determined directly from the plasma con-
centration-time data. The area under the plasma concentration-time curve from
time zero to 12 h postdosing (AUC12) was calculated by use of the linear
trapezoidal rule. The value of the peak-to-trough rate constant () was obtained
from the slope of the least-squares regression of the logarithms of the plasma
concentration-versus-time data for the 12-h interval, which was then used to
calculate the half-life (t1/2). The dosing interval or peak-to-trough t1/2 was cal-
culated as ln 2/. The apparent oral clearance value (CL/F), where F is the
bioavailability, was calculated by dividing the administered dose in a dosing
interval by AUC12. CL/F was normalized for body weight (CL/F.kg) by dividing
by the weight (in kilograms). The apparent volume of distribution (V/F) was
calculated by dividing CL/F by . V/F was normalized for body weight (V/F.kg)
by dividing by the weight (in kilograms).
Statistical analysis. The pharmacokinetic data for lopinavir, ritonavir, and
rifampin are presented as arithmetic means standard deviations and geometric
means. The data were logarithmically transformed for the calculation of geo-
metric means. The median and interquartile ranges are presented for Tmax. The
change in a pharmacokinetic variable for lopinavir or ritonavir from the admin-
istration of lopinavir-ritonavir alone to the administration of the combination
regimen with rifampin was analyzed by a paired t test for each of the study arms.
A Wilcoxon signed-ranks test was used for Tmax. P values less than 0.05 were
considered statistically significant. Variables included logarithmically trans-
formed AUC12, Cmin, C0, and Cmax and nontransformed Tmax and t1/2. The
bioavailability ratio for the combination regimen relative to that for lopinavir
alone was assessed by the two one-sided-tests procedure with 90% confidence
intervals for AUC12, Cmin, C0, and Cmax. For this purpose geometric mean ratios
were calculated by dividing the geometric mean values for study day 24 by the
geometric mean values for study day 10. The 90% confidence intervals of the
geometric mean ratios were obtained by exponentiating the confidence limits for
the differences in logarithmic means. The geometric mean ratios together with
the 90% confidence intervals were compared to the range of 0.80 to 1.25 to
determine whether the lopinavir-ritonavir dose regimens combined with ri-
fampin met the criteria for bioequivalence to the standard clinical dose of
lopinavir-ritonavir.
Additionally, lopinavir C0s on study day 7 versus those on study day 10 and
lopinavir C0s on study day 22 versus those on study day 24 were tested by the
paired-samples t test to evaluate whether steady state was achieved.
A power calculation was performed in the development phase of the study.
The calculation, based on the lopinavir C0, indicated that data for nine subjects
were needed in each study arm. As a dropout rate of 40 to 50% was assumed, 16
subjects were included in each study arm.
RESULTS
Subjects. Thirty-two subjects (18 males, 14 females) were
included in the study, of which 20 completed the study. Twelve
subjects dropped out for reasons of adverse events or labora-
tory abnormalities. Data for all 32 subjects participating in the
study were included in the safety analyses. Pharmacokinetic
data for 1 of the 20 subjects who completed the study were not
evaluable due to vomiting shortly after drug administration on
day 24. For this reason, statistical analyses for pharmacokinet-
ics were performed with data for 19 subjects, 10 in arm 1 and
9 in arm 2.
The 10 subjects in arm 1 (4 males, 6 females) had a mean age
of 37 years (range, 22 to 70 years), a mean height of 1.70 m
(range, 1.61 to 1.85 m), and a mean weight of 70.6 kg (range,
61.5 to 77.0 kg). Of these 10 subjects, 1 was black; all others
were Caucasian.
The nine subjects in arm 2 (7 males, 2 females) had a mean
age of 36 years (range, 25 to 47 years), a mean height of 1.80 m
(range, 1.58 to 1.90 m), and a mean weight of 75.4 (range, 60.5
to 85.4 kg). All nine subjects in arm 2 were Caucasian.
Lopinavir pharmacokinetics. Figure 1 shows the arithmetic
mean standard deviation trough lopinavir levels in plasma in
the morning obtained during the study. Trough lopinavir levels
in plasma were not statistically different between days 7 and 10,
suggesting that in both arms steady state was reached after 10
days of treatment with lopinavir-ritonavir at 400/100 mg BID
(P	 0.5 and P	 0.5 for comparison of C0s on day 7 versus that
on day 10 for arms 1 and 2, respectively). On study day 16
(when lopinavir-ritonavir at 400/100 mg BID was combined
with rifampin at 600 mg QD), trough lopinavir levels decreased
93% in arm 1 and 90% in arm 2 in comparison to those on
study day 10. Trough lopinavir levels increased in both study
arms after lopinavir-ritonavir dosages were titrated to 800/200
mg BID in arm 1 and 400/400 mg BID in arm 2 and adminis-
tered in combination with rifampin at 600 mg QD (days 18, 20,
22, and 24). Trough lopinavir levels in plasma were not statis-
tically different between days 22 and 24, suggesting that steady
state was reached (P 	 0.7 and P 	 0.15 for comparison of C0s
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on day 22 versus those on day 24 for arms 1 and 2, respec-
tively).
The values for the lopinavir pharmacokinetic parameters are
summarized in Table 2. Arithmetic means  standard devia-
tions and geometric means are included for study days 10 and
24 for both arm 1 and arm 2. Note that these geometric means
result in values different from the arithmetic means in Fig. 1
and 2. The P values for the within-subject differences between
days 10 and 24 are presented in Table 2 as well. Table 2 also
presents the geometric mean ratio (day 24/day 10) and the 90%
confidence interval for AUC12, Cmin, C0, and Cmax. For arm 1
(n 	 10; lopinavir-ritonavir at 800/200 mg BID in combination
with rifampin at 600 mg QD), no statistically significant differ-
ences were observed between the values of the pharmacoki-
netic parameters for days 10 and 24. Due to intersubject vari-
ability, the geometric mean ratio and matching confidence
interval met the criteria for bioequivalence only for Cmax. Geo-
metric mean ratios for Cmin and C0 showed decreases of 57 and
54%, respectively, from days 10 to 24, and the lopinavir AUC12
for arm 1 decreased by 16%. The total variability (coefficient of
variation) in the lopinavir Cmin in arm 1 was 28% on day 10,
whereas it was 81% on day 24. Figure 2 displays the arithmetic
mean plasma-concentration time profiles for lopinavir in arm 1
for both study day 10 and study day 24. The error bars in Fig.
2 show this larger variability on day 24.
In arm 2 (n 	 9; lopinavir-ritonavir at 400/400 mg BID in
combination with rifampin at 600 mg QD), the geometric
mean ratios and their matching confidence intervals meet the
criteria for bioequivalence for AUC12 and Cmax (Table 2).
Although the geometric mean ratios are within 11% of unity
for Cmin (3%) and C0 (11%), the 90% confidence intervals
for the geometric mean ratios of Cmin and C0 exceed both the
upper and the lower limits of the predefined bioequivalence
range of 0.80 to 1.25. No statistically significant differences
FIG. 1. Trough lopinavir levels throughout the study. Treatments
were as follows: days 1 to 10, lopinavir-ritonavir at 400/100 mg BID;
days 11 to 15, lopinavir-ritonavir at 400/100 mg BID plus rifampin;
days 16 and 17, lopinavir-ritonavir dose escalation plus rifampin; days
18 to 24, lopinavir-ritonavir at 800/200 mg BID plus rifampin for arm
1 and lopinavir-ritonavir at 400/400 mg BID plus rifampin for arm 2. F,
arm 1 (n 	 10); , arm 2 (n 	 9). Data are presented as arithmetic
means, and error bars indicate standard deviations.
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between the values of the pharmacokinetic parameters ob-
tained on days 10 and 24 were observed. The total variabilities
(coefficients of variation) in lopinavir Cmins in arm 2 on days 10
and 24 were 36 and 46%, respectively. Figure 2 displays the
arithmetic mean plasma-concentration time profiles for lopi-
navir in arm 2 for both study day 10 and study day 24. The error
bars in Fig. 2 represent the standard deviation of the mean and
show variabilities of the same magnitude on both study days.
Ritonavir pharmacokinetics. The values of the steady-state
pharmacokinetic parameters for ritonavir are summarized in
Table 3. Arithmetic means  standard deviations and geomet-
ric means are included for study days 10 and 24 for both arm
1 and arm 2. The P values for the within-subject differences
between days 10 and 24 are displayed as well. The geometric
mean ratio (day 24/day 10) and 90% confidence interval are
given for AUC12, Cmin, C0, and Cmax. Geometric mean ratios in
arm 1 showed increases in AUC12, Cmin, C0, and Cmax of 42, 11,
17, and 75%, respectively, with an increase in the ritonavir
dosage from 100 to 200 mg BID from days 10 to 24. A statis-
tically significant difference in the ritonavir Cmax was found
between study days 10 and 24 (P 	 0.01). No statistically
significant differences in Cmin, C0, and AUC12 were observed.
In arm 2, geometric mean ratios showed increases in the
ritonavir AUC12, Cmin, C0, and Cmax of 7.1-, 4.9-, 4.7-, and
8.4-fold, respectively, with the increase in the ritonavir dosage
from 100 to 400 mg BID from days 10 to 24. These differences
were statistically significant for AUC12, Cmin, C0, and Cmax
from days 10 to 24 (P  0.001 for all comparisons) (Table 3).
No significant differences in Tmax or t1/2 were observed in
either arm.
Rifampin pharmacokinetics. The values of the steady-state
pharmacokinetic parameters for rifampin on day 24 are pre-
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FIG. 2. Lopinavir steady-state concentration-time profiles. , arm
1 (n 	 10) with lopinavir-ritonavir at 400/100 mg BID (day 10); E, arm
1 (n 	 10) with lopinavir-ritonavir at 800/200 mg BID plus rifampin
(day 24); Œ, arm 2 (n 	 9) with lopinavir-ritonavir at 400/100 mg BID
(day 10); ƒ, arm 2 (n 	 9) with lopinavir-ritonavir at 400/400 mg BID
plus rifampin (day 24). Data are presented as arithmetic means, and
error bars indicate standard deviations.
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sented in Table 4. Arithmetic means standard deviations and
geometric means are displayed. Data are grouped by study
arm; arm 1 denotes lopinavir-ritonavir at 800/200 mg BID in
combination with rifampin at 600 mg QD, and arm 2 denotes
lopinavir-ritonavir at 400/400 mg BID in combination with
rifampin at 600 mg QD. No statistically significant differences
in rifampin pharmacokinetics between arms 1 and 2 were
found.
Adverse events. Most (87%) of the adverse events were mild.
Three adverse events (not related to a study medication) were
reported to be severe; these were cases of gastroenteritis, in-
fluenza, and headache. Serious adverse events did not occur.
Twelve of 32 subjects (38%) were prematurely discontinued
from the study; 3 of these subjects discontinued the study prior
to randomization (while receiving lopinavir-ritonavir at 400/
100 mg BID alone). One subject was prematurely discontinued
from the study for grade 2 total bilirubin level elevations (
31
mol/liter), which predominantly consisted of indirect biliru-
bin. However, this subject did not have concurrent grade 2
ALAT, ASAT, or alkaline phosphatase level elevations. One
additional subject was prematurely discontinued from the
study for grade 3 elevations in cholesterol levels (
7.77 mmol/
liter) and triglyceride levels (
8.48 mmol/liter), both of which
subsequently declined to below grade 3 elevations following
discontinuation of the study medication. A third subject was
prematurely discontinued from the study for a complex of
vomiting and abdominal pain. These complaints disappeared
after the study medication was discontinued. There were half
as many subject discontinuations in arm 1 (lopinavir-ritonavir
at 800/200 mg BID and rifampin at 600 mg QD; three subjects
discontinued the medication; one subject developed grade 2
elevations in ASAT, ALAT, and GGT levels; one subject de-
veloped a grade 2 elevation in ASAT levels and a grade 3
elevation in ALAT levels; and one subject suffered from vom-
iting and diarrhea) as in arm 2 (lopinavir-ritonavir at 400/400
mg BID with rifampin at 600 mg QD; six subjects discontinued
the medication; three subjects developed grade 2 elevations in
ASAT and ALAT levels; two subjects developed grade 2 ele-
vations in ALAT levels; and one subject suffered from nausea,
abdominal pain, fatigue, shivers, and increased sweating).
During the study, six subjects (two in arm 1, four in arm 2)
had grade 2 elevations in ALAT levels (
2.6 times the ULN)
and three subjects (one in arm 1, two in arm 2) had grade 3
elevations in ALAT levels (
5.1 times the ULN). Five of these
subjects experienced concurrent grade 2 elevations in ASAT
levels (
2.6 times the ULN). Seven of the nine subjects with
grade 2 to 3 elevations in ALAT levels (two in arm 1, five in
arm 2) were prematurely discontinued from the study. The
other two subjects developed elevations in liver enzyme levels
on or after study day 24.
The onset of all grade 2 or 3 elevations in ALAT and ASAT
levels was after the initiation of rifampin treatment, but none
of these were associated with grade 2 elevations in total
bilirubin or alkaline phosphatase levels. After discontinuation
of the study medication, all such elevations declined below
those for grade 2 toxicity, with only two remaining above the
ULN at the final study evaluation.
Laboratory measurements. The mean change from the base-
line values to the maximum values as well as the mean change
from the baseline values to the final values was determined for
a number of laboratory parameters. The baseline was day 1 for
the period from day 1 to 10, and the baseline was day 10 for the
period from days 11 to 24. For ASAT, the mean changes from
the baseline value (day 10) to the maximum value (final value)
were 39.9 (2.4) and 39.9 (1.1) IU/liter in arms 1 and 2, respec-
tively, for study days 11 to 24. For ALAT, the mean changes
from the baseline value (day 10) to the maximum value (final
value) were 72.6 (13.5) and 89.3 (6.9) IU/liter in arms 1 and 2,
respectively, for study days 11 to 24. For alkaline phosphatase,
the mean changes from the baseline value (day 10) to the
maximum value (final value) were 12.9 (3.0) and 16.3 (5.0)
IU/liter in arms 1 and 2, respectively, for study days 11 to 24.
No clinically relevant changes in ASAT, ALAT, and alkaline
phosphatase levels were seen on study days 1 to 10 (lopinavir-
ritonavir at 400/100 mg BID alone). For total bilirubin, the
mean change from the baseline value (day 1) to the maximum
value (final value) was 10 (4.7) mol/liter for study days 1 to
10. For study days 11 to 24, the mean changes in the total
bilirubin level from the baseline value (day 10) to the maxi-
mum value (final value) were 0.9 (9.1) and 1.3 (3.9) mol/
liter in study arms 1 and 2, respectively.
DISCUSSION
In the present study, two adjusted-dose regimens of lopina-
vir-ritonavir in combination with rifampin were compared to
the standard dose of lopinavir-ritonavir without rifampin. The
steady-state pharmacokinetics of lopinavir and ritonavir were
determined after 10 days of treatment with the standard dose
of lopinavir-ritonavir (400/100 mg BID). In the second part of
the study, the steady-state pharmacokinetics of lopinavir-
ritonavir at 800/200 mg BID with rifampin at 600 mg QD (arm
1) and lopinavir-ritonavir at 400/400 mg BID with rifampin at
600 mg QD (arm 2) were assessed.
Lopinavir. Lopinavir exposure was substantially higher in
both study arms compared to the historical data obtained for
lopinavir-ritonavir at 400/100 mg BID in combination with
rifampin at 600 mg QD. This historical interaction study with
a standard dose of lopinavir-ritonavir with rifampin was con-
ducted with 22 healthy subjects to assess the effects of multiple
TABLE 4. Steady-state pharmacokinetics of rifampin on study day 24
Arma AUC12 (mg · h/liter) Cmax (mg/liter) Tmax (h) t1/2 (h) CL/F · kg (liter/h · kg) V/F  kg (liter/kg)
Arm 1 79.2  33.84 (72.2)b 14.2  5.61 (13.0) 4.0 (3.0–4.0)c 3.1  1.75 (2.8) 0.12 0.06 (0.11) 0.45 0.16 (0.43)c
Arm 2 76.6  31.87 (70.3) 15.0  3.80 (14.5) 4.0 (3.0–4.0) 2.5  1.33 (2.2) 0.11 0.06 (0.10) 0.34 0.10 (0.33)
a Arm 1 (n 	 10), lopinavir-ritonavir at 800/200 mg BID; arm 2 (n 	 9), lopinavir-ritonavir at 400/400 mg BID.
b Values are arithmetic means  standard deviations (geometric means) unless indicated otherwise.
c Values are medians (interquartile ranges).
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doses of rifampin at 600 mg QD on the pharmacokinetics of
lopinavir after treatment with lopinavir-ritonavir at 400/100 mg
BID. The values of the pharmacokinetic parameters for lopi-
navir were substantially reduced by the coadministration of
lopinavir-ritonavir with rifampin, as follows: Cmax by 45%,
AUC by 75%, and Cmin by 99% (Bertz et al., 5th Int. Congr.
Drug Ther. HIV Infect., abstr. P291, 2000).
While the concentrations of lopinavir are dramatically in-
creased when lopinavir-ritonavir is used in combination with
rifampin with both of the dosing regimens, it could not be
demonstrated that the adjusted-dose regimens with rifampin
evaluated in the present study were equivalent, particularly
with respect to Cmin, to the standard dose of lopinavir-ritonavir
without rifampin. This indicates that the adjusted-dose regi-
mens may in some cases not be capable of completely com-
pensating for the accelerated metabolism of lopinavir by ri-
fampin. Data are also limited by the relatively small number of
subjects who completed the study and for whom pharmacoki-
netic data were evaluable. However, the level of lopinavir ex-
posure in arm 2 was more comparable to that obtained with a
standard dose lopinavir-ritonavir without rifampin than was
the level of lopinavir exposure in arm 1. The pharmacokinetics
of lopinavir in arm 1 were more variable than those in arm 2.
It could be that the higher dose of ritonavir given in arm 2 (400
mg BID) resulted in a more consistent inhibition of lopinavir
metabolism compared to that achieved with the ritonavir dose
given in arm 1 (200 mg BID). Note that on study day 24, a total
of 4 of 10 subjects (40%) in arm 1 had a Cmin lower than the
lowest value observed on study day 10 (Cmin,3.7 mg/liter). In
contrast, only one of the nine subjects (11%) in arm 2 had a
Cmin lower than the lowest value observed on study day 10
(Cmin, 3.1 mg/liter). The study was not designed to show a
difference in lopinavir exposures between study arms. How-
ever, by taking into account the greater variability in lopinavir
pharmacokinetics in arm 1, therapeutic drug monitoring might
prove to be useful in clinical practice to monitor for possible
subtherapeutic Cmins of lopinavir in plasma and individually
optimize the lopinavir-ritonavir dosing regimen in a given pa-
tient. In arm 2, the Cmins of lopinavir in plasma tended to be
higher, possibly making therapeutic drug monitoring of less
importance.
Ritonavir. For ritonavir, it is apparent that in arm 1 a two-
fold increase in the ritonavir dose from 200 mg/day in the
absence of rifampin to 400 mg/day in the presence of rifampin
resulted in a less than proportional increase in plasma ritonavir
concentrations. In arm 2, considerably higher plasma ritonavir
concentrations were achieved during treatment with lopinavir-
ritonavir at 400/400 mg BID in combination with rifampin
compared to those achieved with lopinavir-ritonavir at 400/100
mg BID alone. In fact, when ritonavir is administered in com-
bination with lopinavir, the ritonavir Cmax and AUC12 increase
more than proportionally due to nonlinear pharmacokinetics
(8) when the total daily dose is increased fourfold from 200
mg/day in the absence of rifampin to 800 mg/day in the pres-
ence of rifampin. The ritonavir AUC12 was approximately
fourfold higher when lopinavir-ritonavir at 400/400 mg BID
was coadministered with rifampin than when lopinavir-ritona-
vir at 800/200 mg BID was coadministered with rifampin.
These observed effects of ritonavir exposure indicate that the
inhibition of CYP3A by ritonavir is more complete and less
subject to induction by rifampin when ritonavir is dosed at 400
mg BID than when it is dosed at 200 mg BID.
Rifampin. Data for rifampin in the literature (2) report a
mean Cmax and a mean AUC of 8 to 20 mg/liter and 60 to 80
mg · h/liter, respectively. The mean values for Cmax and AUC
observed in this study are within these ranges (Table 4). This
indicates that lopinavir-ritonavir does not affect the pharma-
cokinetics of rifampin. The fact that no statistically significant
differences in the pharmacokinetic parameters for rifampin
were observed between arm 1 and arm 2, as shown in Table 4,
provides further evidence that these different doses of lopina-
vir and ritonavir had no influence on rifampin exposure. The
literature also reports (2, 12) that rifampin intake with food
can decrease the rifampin Cmax. It is noteworthy that in the
present study rifampin was administered with lopinavir-ritona-
vir at breakfast (550 kcal, 28% fat). Nevertheless, in this study
the rifampin Cmax did not show the decrease that has been
reported before. Data in the literature indicate that the Tmax is
1.5 to 2.0 h under fasting conditions. In a trial studying the
single-dose pharmacokinetics of rifampin under fasting condi-
tions (12), with food, and with antacids, the observed Tmax was
4.43 h after a high-fat breakfast (792 kcal, 57% fat). In the
present study, the median Tmax was about 4 h in both study
arms; this delay of Tmax was probably the result of the intake
with food. However, in clinical practice, the rifampin Cmax is
the main pharmacokinetic parameter of interest (2). There-
fore, the clinical relevance of the delay in Tmax is limited, as in
the present study the mean Cmaxs were well within the previ-
ously reported ranges (2).
Safety. The most common adverse events, reported by

50% of subjects, included urine discoloration, which is a
known effect of rifampin therapy (5); nausea; headache; diar-
rhea; abdominal pain and cramps; and fatigue. The majority of
all adverse events were mild (87%), with approximately 13%
judged to be of moderate severity and only three events (gas-
troenteritis, influenza, and headache) reported to be severe.
None of the adverse events met the regulatory definition of
serious. A number of subjects had to discontinue the study
prematurely due to elevations in liver function test results, with
the onset of the elevations occurring after the initiation of
combination lopinavir-ritonavir and rifampin dosing. A greater
number of discontinuations occurred among the subjects in the
arm receiving lopinavir-ritonavir at 400/400 mg BID plus ri-
fampin at 600 mg QD. However, the study design did not allow
an assessment of whether the frequency or magnitude of the
elevations in the liver function test results seen with lopinavir-
ritonavir in combination with rifampin was different between
the study arms. No clinically significant hematology or urinal-
ysis values were observed in the study.
Overall, tolerability limitations were observed with the co-
administration of lopinavir-ritonavir and rifampin in healthy
subjects. The high rate of discontinuations observed was pri-
marily a result of the elevations in the liver function test results
that occurred after the initiation of lopinavir-ritonavir and
rifampin coadministration. However, there was no dosing seg-
ment with rifampin alone to allow determination of whether
the liver function test abnormalities observed during combina-
tion lopinavir-ritonavir and rifampin treatment were of a
greater magnitude or incidence than would have been ob-
served with rifampin administration alone to healthy subjects.
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Nevertheless, the increased rate of elevations in hepatic
transaminase levels seen in both combination-treatment arms
warrants the use of caution when these two drugs are admin-
istered concurrently to patients infected with both HIV and M.
tuberculosis.
Conclusions. The present recommendations from the Cen-
ters for Disease Control and Prevention indicate that rifampin
can be used in conjunction with efavirenz at 800 mg QD (4).
The combination of efavirenz with rifampin has been studied
in a group of 24 HIV-infected patients coinfected with M.
tuberculosis (10). Other combination regimens that have been
considered for use for the simultaneous treatment of HIV and
M. tuberculosis infections are limited.
The combination of saquinavir-ritonavir at 400/400 mg BID
with rifampin, as mentioned in the Introduction, has its paral-
lels with the combination evaluated in the present study. How-
ever, the data for the saquinavir-ritonavir combination were
only presented as a case report.
The product Trizivir combines three NRTIs, namely, zidovu-
dine, lamivudine, and abacavir, and could be an option for use
in combination with rifampin. Nevertheless, the pharmacoki-
netics of this combination of NRTIs in combination with ri-
fampin were not studied, and recently, this combination of
NRTIs was shown to be less effective than an efavirenz-based
regimen (7) and therefore will not be an option of first choice.
Centers for Disease Control and Prevention guidelines also
suggest the use of rifabutin (3, 4). However, complex bidirec-
tional interactions are to be expected when rifabutin is com-
bined with PIs (2). To compensate for these interactions, ri-
fabutin doses must be decreased in some cases, or the PIs
should be given at higher doses to compensate for accelerated
metabolism. The combination of rifabutin with the NNRTIs
efavirenz and delavirdine results in pharmacokinetic interac-
tions as well (4); however, nevirapine can be used in combina-
tion with rifabutin, although no data from clinical studies have
been published (4). It was reported from a study with HIV-
infected inmates during a tuberculosis outbreak in a prison
that, regardless of the rifabutin dosage, rifabutin concentra-
tions are highly unpredictable, probably due to drug-drug in-
teractions (16). From these data it becomes clear that the
combination of rifabutin with PIs or NNRTIs remains a ther-
apeutic challenge.
The presently studied combination of lopinavir-ritonavir,
dosed as either 800/200 mg BID or 400/400 mg BID with
rifampin, may be considered for the treatment of HIV-infected
persons who are coinfected with M. tuberculosis. The toxicity
observed when higher-dose lopinavir-ritonavir and rifampin
were administered together led to discontinuation in 31% (9 of
29) of the healthy subjects during this study. When these drugs
are used to treat patients who use other hepatically metabo-
lized drugs, who are receiving long-term chronic treatment, and
who have concomitant disease, the adverse event profile observed
in the present study might even worsen. Therefore, the treatment
of HIV-infected patients with tuberculosis with these agents
should be approached with caution, and close monitoring of liver
function will be needed. Therapeutic monitoring of the pharma-
cokinetics of lopinavir may be useful for the detection of minimal
levels in plasma that are markedly below the expected mean,
particularly in those patients treated with 800/200 mg BID, as well
as to optimize the dosing regimen of lopinavir-ritonavir in com-
bination with rifampin. If therapeutic drug monitoring is not pos-
sible, the combination of lopinavir and ritonavir at 400/400 mg
BID may be preferred, although the rates of elevations in liver
function test results achieved with that regimen tended to be
higher than those achieved with the lopinavir-ritonavir regimen of
800/200 mg BID.
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